-
2011
November - Shanghai OMNI Pharmaceutical Technology Co., Ltd. was established.
-
2012
June - The core team was built
-
2013
February - Suzhou OMNI Pharmaceutical Co. Ltd was established.
March - Series A financing was completed.
OMNI was included in Taicang Overseas Returnee Program for Scientific Innovation and Entrepreneurship
OMNI received funding support from Taicang Foreign Trade Public Service Platform Construction Project
-
2014
April - DPI/MDI production lines were finished at the Suzhou site.
-
2015
September - Series B financing was completed.
OMNI received Gusu Angel Investment for Science and Technology Start-ups
-
2016
October - OMNI’s MDI and DPI products were on the list for the pilot reform of the Market Authorization Holder (MAH) system in Shanghai
OMNI received funding for the Drug Consistency Evaluation technical service platform from Taicang City Service Industry Funding Support Project
-
2017
October - Series C financing of RMB 260 million was completed.
-
2018
April - Haimen OMNI Pharmaceutical Co. Ltd was established.
December - OMNI was awarded as 2018 Zhangjiang Top 100 Enterprise.
December - OMNI was ranked 48th on the 2018 Future Top 100 Healthcare Companies List and China’s TOP100 Pharmaceutical Company List
OMNI was recognized as the economic transformation and upgrading project of Taicang Bureau of Commerce
-
2019
February - Shanghai operation center was unveiled.
March - Haimen OMNI Pharmaceutical Co. Ltd. started operation.
-
2021
April - OMNI mergered with SMC to improve the marketing system of OMNI
December-OMNI completed hundreds of millions of yuan in D round of financing
-
2022
September - NMPA approves shifeichang in patients with reversible airway obstruction
November - OMNI Pharma held the launch ceremony of the new inhalation preparation industrialization project
-
2023
February - OMNI Pharma was selected in the list of "Potential Unicorn" enterprises in Jiangsu and the list of "unicorn" cultivating enterprises in Suzhou in 2022
July-OMNI's Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation has been submitted for listing application and officially accepted by CDE
